Ensign Peak Advisors
TVTX icon

Ensign Peak Advisors’s Travere Therapeutics TVTX Stock Holding History

Ensign Peak Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.3M Sell
715,707
-89,508
-11% -$2.68M 0.04% 297
2025
Q4 		$30.8M Sell
805,215
-46,987
-6% -$1.53M 0.05% 240
2025
Q3 		$20.4M Sell
852,202
-6,632
-0.8% -$125K 0.03% 308
2025
Q2 		$12.7M Buy
858,834
+360,100
+72% +$5.97M 0.02% 416
2025
Q1 		$8.94M Buy
+498,734
New +$10.1M 0.02% 493
2023
Q3 		– Sell
-110,088
Closed -$1.69M – 1765
2023
Q2 		$1.69M Hold
110,088
– – ﹤0.01% 941
2023
Q1 		$2.48M Buy
110,088
+32,858
+43% +$698K 0.01% 755
2022
Q4 		$1.62M Sell
77,230
-20,100
-21% -$426K ﹤0.01% 893
2022
Q3 		$2.4M Buy
97,330
+20,431
+27% +$528K 0.01% 720
2022
Q2 		$1.86M Buy
76,899
+65,819
+594% +$1.66M ﹤0.01% 829
2022
Q1 		$286K Buy
+11,080
New +$294K ﹤0.01% 1770

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ensign Peak Advisors's TVTX Position: Q1 2026 in Review

Ensign Peak Advisors reduced its Travere Therapeutics (TVTX) stake by 11% in Q1 2026, selling an estimated $2.68M and leaving 715,707 shares worth $21.3M. The position accounts for 0.04% of the portfolio, ranked #297.

Ensign Peak Advisors first reported a position in TVTX in Q1 2022 and has held it in 11 quarters since. The position peaked at $30.8M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Ensign Peak Advisors held 715,707 shares of Travere Therapeutics worth $21.3M as of Q1 2026.
  • Ensign Peak Advisors sold 89,508 Travere Therapeutics shares in Q1 2026, an estimated $2.68M.
  • Travere Therapeutics made up 0.04% of Ensign Peak Advisors's portfolio in Q1 2026, its #297 holding.
  • Ensign Peak Advisors first reported a position in Travere Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • Ensign Peak Advisors's Travere Therapeutics position peaked at $30.8M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.